Videos

The experts present and discuss the case of a patient with steroid-refractory chronic GVHD and discuss treatment options.

Constantine S. Tam, MD, discusses how ibrutinib plus venetoclax regimen from the SYMPATICO 2938 trial may fit in the relapsed/refractory mantle cell lymphoma setting.

Thomas Marron, PhD, MD, discusses the safety and tolerability of neoadjuvant sunitinib in hepatocellular carcinoma.

Charles Powell, MD, MBA, discusses the questions surrounding pulmonary toxicities when using anti-HER2 monoclonal antibodies such as trastuzumab deruxtecan for patients with HER2-positive metastatic breast cancer.

Annelise Wilhite, MD, discusses a clinical investigation of survival in patients with vulvar/vaginal melanomas.

Melissa, K. Frey, MD, the study of adequate collection of family cancer history in ovarian and other gynecological cancers in order to determine cancer risk and early interventions.

Robert Coleman, MD, FACOG, FACS, discusses key advances in precision medicine in lung cancer.

The panelists discuss the role of ruxolitinib steroid-refractory acute GVHD and comment on unmet needs in treating this patient population, including fecal transplants.

Understanding the importance of having a multidisciplinary team in the treatment of acute GVHD, panelists discuss the NCCN Guidelines and REACH2 trial.

Dr Prithviraj Bose reviews treatment options in the setting of hydroxyurea failure in patients with polycythemia vera.

Experts in polycythemia vera discuss decision-making around when to initiate cytoreductive therapy in patients with low risk polycythemia vera.

Vivek Subbiah, MD, discusses the updated results of the LIBRETTO-001 trial, specifically the effect of selpercatinib on RET fusion-positive thyroid tumors.

Brian Van Tine, MD, PhD, and Fadi Braiteh, MD, discuss unmet needs in the treatment of gastrointestinal stromal tumors (GISTs) and look to the future in terms of the evolving field.

Experts discuss the role of multidisciplinary management for patients with gastrointestinal stromal tumors (GISTs).

John N. Allan, MD, discusses a pooled analysis of 4 clinical trials with 4-year follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia and TP53 aberration deletion 17p or a TP53 mutation.

An expert in gastric cancers provides insight on the recent advances and future directions for the management of locally advanced and metastatic gastric cancers.

Dr John Marshall discuss the DESTINY-Gastric01 trial and the implications of the study results to clinical practice for HER2+ metastatic gastric cancer.

John Marshall, MD, reviews options for second- and later line therapies and considerations for treatment sequencing in patients with HER2+ gastric cancers.

Dr John Marshall discusses frontline systemic treatment options for metastatic HER2+ gastroesophageal junction cancer and gastric cancer in general.

An expert in gastric cancers describes when and for whom molecular testing should be done in patients with metastatic HER2+ gastric cancer, and which tests are move relevant to treatment decision-making.

John Marshall, MD, reviews the case of a patient with metastatic HER2+ (human epidermal growth factor receptor 2) gastroesophageal junction cancer.

Xiuning Le, MD, PhD, discusses the reasoning behind splitting the dose of poziotinib dose in order to reduce adverse effects and improve efficacy for the treatment of EGFR- or HER2 exon 20–positive non–small cell lung cancer.

Erika P. Hamilton, MD, discusses the data leading up to the Next MONARCH 1 study of abemaciclib plus tamoxifen or abemaciclib alone with metastatic breast cancer.

John Burke, MD, provides clinical pearls in the recognition in treatment of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).

John Burke, MD, reflects on current novel therapies used in the treatment of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).

John Burke, MD, reviews the practical implications and role of tafasitamab and lenalidomide in addition to reviewing significant results from the L-MIND trial.

John Burke, MD, considers factors for initiating second-line treatment in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).

John Burke, MD, discusses frontline treatment options for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).

John Burke, MD, presents a case of a 76-year-old man with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).

Experts discuss the treatment considerations for acute GVHD, the role of molecular testing, and considerations for steroid-refractory acute GVHD.